Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

Overview

This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 11, 2021

Detailed Description

Primary scarring alopecias (PSAs) are poorly understood dermatologic disorders that result in permanent hair loss. Most of the scarring alopecias involve a painful course, with individuals reporting scalp pain, burning, itching, or tingling/crawling sensations that can ultimately impact physical and psychological health. There has been no study of topical neurogenic agents, such as gabapentin, to treat scarring alopecia. However topical gabapentin has been safely used in other conditions associated with chronic pain, burning, irritation, itch, or tingling, such as vulvodynia. This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia. In this study, 10 subjects with symptomatic lymphocytic-type scarring alopecia will be recruited and treated with topical gabapentin. Disease burden will be evaluated before and after 12 weeks of treatment through reporting of subjective symptomatology via surveys/questionnaire, neurometer study, clinical assessment, and biopsies measuring levels of CGRP before and after treatment.

Interventions

  • Drug: Topical gabapentin
    • topical gabapentin 6% solution

Arms, Groups and Cohorts

  • Experimental: Topical gabapentin
    • gabapentin 6% solution, 1mL applied twice daily for 12 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Neurogenic inflammation-QOL
    • Time Frame: Change from Baseline to 14 weeks
    • Complete a QOL (Quality of Life) survey Scale= (Not relevant to Extremely Relevant)
  • Neurogenic inflammation-Short Form (36) Health Survey
    • Time Frame: Change from Baseline to 14 weeks
    • Complete Short Form (36) Health Survey Scale Scale=1-5 1 being the best and 5 being the worse
  • Neurogenic inflammation- Visual Analog pain Scale
    • Time Frame: Change from Baseline to 14 weeks
    • Visual Analog Pain scale Scale = 1-10 1 being the least pain and 10 being the worse pain

Secondary Measures

  • Safety and efficacy of topical 6% gabapentin -Medication side Effects
    • Time Frame: Change from Baseline to 12 weeks
    • Subjects will have Medication side effects collected at day 0 and ending week 12
  • Safety and efficacy of topical 6% gabapentin -Blood levels
    • Time Frame: Change from Baseline to 12 weeks
    • Subjects will have blood levels measured at Day 0 and 12 weeks
  • Safety and efficacy of topical 6% gabapentin -Adverse Events
    • Time Frame: Change from Baseline to 12 weeks
    • Subjects will have adverse events collected on day 0 and 12 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. Male and female adults, greater than 18 years of age 2. Biopsy-proven diagnosis of primary scarring alopecia of lymphocytic inflammatory infiltrate type, indicated as one of the following conditions: lichen planopilaris, frontal fibrosing alopecia, or central centrifugal cicatricial alopecia 3. At least one persistent scalp symptom associated with inflammation: pain, burning, itch, tingling/crawling, stinging, or tenderness 4. Able to complete survey and questionnaire subjectively 5. Consents to participate in neurometer study and scalp biopsy acquisition 6. Willingness to adhere to study protocol 7. If subject is taking a neuromodulatory medication (including capsaicin cream, tricyclic antidepressants, carbamazepine, phenytoin, topiramate, oxcarbazepine, lamotrigine, morphine, Botox, etc), he or she must be a stable dose for at least 6 months prior to study enrollment Exclusion Criteria:

1. Allergy or intolerance to gabapentin or the substances used in its compounding 2. Underlying disease that might be adversely affected by topical gabapentin 3. Application of topical immunomodulatory or immunosuppressive agent to the scalp in the preceding 2 weeks 4. Systemic administration of corticosteroid or other systemic treatment (i.e., methotrexate, phototherapy) that has immunomodulatory or other immunosuppressive mechanism of action, in the preceding 8 weeks 5. Clinical evidence of secondary skin infection 6. Individuals who have undergone scalp reduction surgery or hair transplantation 7. Asymptomatic disease 8. Immunosuppression due to disease state or use of systemic/topical biological agents (HIV, chemotherapy, immunomodulators, history of transplantation) 9. Any Investigational medications within the past 30 days, including those for migraines or scarring alopecias (anti-CGRP agents) 10. Use of GABAergic medications (including gabapentin and pregabalin) in the preceding 2 months 11. Use of illicit drugs or opioid medications 12. Evidence of anemia, thyroid disease, sarcoidosis or other medical condition that could impact hair growth and adversely impact the outcome of the study 13. Implantable Cardioverter Defibrillator (ICD) or pacemaker 14. Subject has any medical condition that, in the judgment of the Investigator, would jeopardize the subject's safety following exposure to the administered medications

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Minnesota
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Maria K Hordinsky, MD, Principal Investigator, University of Minnesota

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.